Ind-Swift Laboratories is trading at INR 389.30, down 5.00%, with no specific catalyst identified for the decline on October 30, 2026.
- Q2 FY27 consolidated net profit was ₹34.2 crore, up 328.3% year over year; revenue was ₹240 crore, up 57.5%.
- The positive results do not explain the drop. Broader-market context was mixed, while the healthcare sector trend was positive.